The consequences of lifelong untreated childhood-onset GH deficiency (COGHD) on adult bone and especially fracture prevalence are largely unknown due to the lack of data on long-term outcome of untreated patients. Therefore, we studied adult Russian patients (n ‫؍‬ 66; 28 females and 38 males) with idiopathic GH-untreated COGHD. Patients had isolated GH deficiency (IGHD; n ‫؍‬ 18, age 23 ؎ 10 yr) or multiple pituitary hormone deficiency (MPHD) with open (OMPHD; n ‫؍‬ 27, age 23 ؎ 5 yr) or closed growth plates (CMPHD; n ‫؍‬ 21, age 55 ؎ 12 yr). Bone mineral content (BMC) and bone mineral density (BMD) values were compared with 821 normal Russian controls. Fracture prevalence was ascertained from medical history and compared with similar data from 333 normal controls.
G
H IS A major regulator of growth plate chondrocytes and bone cells. Lifelong GH deficiency (GHD) not only impairs linear growth but also decreases the threedimensional size (volume) of bone (1) (2) (3) . Therefore, peak bone mass is decreased in such patients, whereas in eugonadal acromegalic patients, bone size and mass are usually increased (2) (3) (4) (5) (6) . In most developed societies, childhoodonset GHD (COGHD) is detected and treated early in life so that large cohorts of untreated COGHD adult patients are no longer available for studying the effects of lifelong GHD on specific tissues. Here, we report on the effects of COGHD (GHD alone or in combination with substituted other pituitary hormone deficiencies) on bone mass, bone size, and fracture prevalence in a cohort of 66 Russian patients who were virtually never treated with GH.
Patients and Methods Patients
Sixty-six adult patients, all Caucasians, were studied (Table 1) . They were recruited from the Moscow Endocrine Research Centre and other Moscow clinics or by dedicated search among artists (circus, theater, and musical academia). Eighteen patients (eight females and 10 males) had isolated GHD (IGHD); 27 (10 females and 17 males) had GHD with multiple pituitary hormone deficiencies (MPHD) and open growth plates (OMPHD) due to delayed sex steroid hormone replacement therapy; and 21 (10 females and 11 males) had GHD with MPHD and closed growth plates (CMPHD). The diagnostic criteria used to establish pituitary hormone deficiencies are presented in Table 2 . All patients with MPHD had combined GHϩTSHϩLH/FSH deficiency. In addition, nine were ACTH deficient, eight were prolactin deficient, and six were ACTH and prolactin deficient. Twenty of 66 patients were working in a circus, but only three performed acrobatic activities. Oral consent to participate in this study was obtained from all subjects.
Hormonal replacement
All IGHD and 25 MPHD patients had never received any GH treatment. In the remaining 23 patients, GH therapy during childhood had been sporadic, with intermittent courses of treatment with pituitaryderived GH. Periods of exposure ranged from 2 months to a maximum of 2 yr (median, 16 months). Replacement with other hormones was made with thyroxine, testosterone propionate, or ethinyl estradiol, and prednisolone (Table 2) . However, compliance with hormonal replacement therapy had not been optimal in some patients.
Clinical case histories were available for all patients, and detailed Abbreviations: BMC, Bone mineral content; BMD, bone mineral density; CMPHD, multiple pituitary hormone deficiency with closed growth plates; COGHD, childhood-onset GH deficiency; DEXA, dualenergy x-ray absorptiometry; GHD, GH deficiency; IGHD, isolated GH deficiency; MPHD, multiple pituitary hormone deficiency; OMPHD, multiple pituitary hormone deficiency with open growth plates. information on number of traumatic and nontraumatic bone fractures was obtained by detailed questionnaires and/or patient records.
Controls
Normal reference values for bone mass [bone mineral content (BMC)] and bone mineral density (BMD) by dual-energy x-ray absorptiometry (DEXA) were obtained from 821 Caucasian adults (494 females and 327 males, age 18 -80 yr) living in the Moscow area and without chronic diseases known to possibly influence bone metabolism. These data were available from the Russian Space Agency Research Program. Reference data for radiogrammetry were collected in 44 age-(Ϯ 2 yr) and sexmatched healthy volunteers. To assess lifetime occurrence of fractures in the normal population, a total of 333 normal Russian adults (mean age Ϯ sd, 40 Ϯ 17 yr; range, 16 -77 yr) were given a detailed questionnaire to collect information on number, type, and cause of fractures.
Methods
For height sd score calculations, the British standards (7) were used. Bone age was determined according to Greulich and Pyle (8) . BMC and BMD of patients and controls were measured at the Space Physiology Department in Moscow using a Hologic QDR-1000/W instrument (Hologic, Inc., Waltham, MA) using standard company software. Quality control data, obtained by scanning regularly a Hologic spine phantom, revealed a variation coefficient of less than 0.5% and no drift in linearity of data. All acquisitions were performed by trained operators in accordance with the technical manual. The measured areal BMD data of the lumbar spine, left femoral neck, and total body were used to calculate apparent or volumetric bone density (9 -11) using the following formulae: L1-L4 ϭ BMDL1-L4/͌(areaL1-L4); femoral neck ϭ BMC femoral neck/(area femoral neck) 2 ; and total body ϭ BMD total body/height. These calculated values are used whenever volumetric bone density results are mentioned in this article.
Radiogrammetry
Semiautomatic measurements with a 0.01-mm readout of periosteal and endosteal width of the second metacarpal were made on the posteroanterior right-hand radiograph by a single observer (J.N.) who was blinded to the study group assignment, as described (12) . The crosssectional area was calculated by subtracting the square of the endosteal from the square of the periosteal diameter assuming a cylindrical model.
Statistical analysis
The data were analyzed using the SAS statistical software (SAS Institute, Inc., Cary, NC). Z scores were calculated for height and BMD values using the appropriate control data. Student's t test was used for group comparison. Group comparison for fracture risk was calculated using the Mann-Whitney U test. Data are presented as mean Ϯ sd.
Results

Demographic and auxological data
Demographic and auxological data are presented in Table  1 . Gender distribution was comparable in all three groups. Although IGHD and OMPHD patients were of comparable age, CMPHD patients were significantly older (P Ͻ 0.001). Mean height sd score values in the three groups ranged from Ϫ4.08 to Ϫ5.27. Eight IGHD and all OMPHD patients had still open epiphyses, resulting in a ratio of bone age to chronological age of 0.89 Ϯ 0.14 in IGHD and 0.55 Ϯ 0.13 in OMGHD patients; the bone age to chronological age ratio was significantly lower in OMGHD than in IGHD patients (P Ͻ 0.02). Actual standing height values varied from 80% (CMPHD) to 84% (IGHD) of the values of age-(Ϯ 2 yr) and sex-matched controls from the Russian DEXA reference population ( Fig. 1 ).
BMC and BMD
BMC was markedly decreased in all groups of patients. When compared with controls, total BMC of the lumbar spine (L1-L4) was significantly decreased in all three groups (% of normal values: OMPHD, 42 Ϯ 13%; CMPHD, 47 Ϯ 11%; All patients were 18 yr or older. The large SD of their age is explained by the inclusion of a single 61-yr-old patient. Twenty of 66 patients were working in a circus, but only three patients were performing acrobatic exercises, whereas the others were not involved in physically demanding circus activities. SDS, SD score; BA/CA, bone age to chronological age ratio.
a P Ͻ 0.001 vs. OMPHD and IGHD. b P Ͻ 0.001 vs. normal Russian control subjects. and IGHD, 54 Ϯ 17%; Fig. 1 ). Relative values of total BMC of the femoral neck and total body were also markedly reduced and only 47-71% of normal (Fig. 1 ). Areal and calculated volumetric bone densities in the three patients groups are shown in Table 3 . Compared with the reference population, areal BMD was severely decreased in all patients (P Ͻ 0.001). The lowest Z score was observed in patients with OMPHD, whereas IGHD and CMPHD patients had a comparable bone deficit. On the other hand, mean values of volumetric BMD were in the normal range in these two groups and were only slightly decreased in OMPHD patients (Z score, Ϫ0.6 to Ϫ1.0).
Radiogrammetry
Radiogrammetry was performed in IGHD and CMPHD patients only. These data are presented in Table 4 . Compared with the age-and sex-matched controls, both IGHD and CMPHD patients had a reduction in the cortical area value of about 30% (IGHD, 70 Ϯ 14% and CMPHD, 68 Ϯ 14% of controls; P Ͻ 0.0005).
Fracture incidence
Nontraumatic fractures were recorded in 28 OMPHD and CMPHD patients who had 70 fractures compared with 67 fractures in the 333 controls. The number of traumatic fractures (car accident and similarly severe trauma) reported in the patient and control groups was eight and 55, respectively. In IGHD patients, only traumatic fractures were recorded (7%, not significant vs. controls). By contrast, 37 and 18% of the young adults with OMPHD had a history of at least one or at least two low-energy fractures, respectively ( Table 5 ). The mean number of low-energy fractures per OMPHD patient was 3-fold higher than observed in the young control subjects (P Ͻ 0.0001). In the older group with CMPHD, the reported prevalence of at least one or at least two low-energy fractures was 62 and 33%, respectively. The mean number of low traumatic fractures per CMPHD patient was 10-fold greater than that observed in the group of older control subjects (P Ͻ 0.0001; Table 5 ). Most nontraumatic fractures were observed in the wrist (n ϭ 24), hand, foot, ribs, or tibia. Few clinical vertebral fractures and no hip fractures were recorded. No radiological data were available to assess the integrity of the lumbar spine.
Discussion
GH action on the growth plate is critical for longitudinal, one-dimensional growth (2, 3). However, GH also acts on periosteal bone apposition (13) and thus affects the threedimensional bone structure as well. Accordingly, GHD does not only affect skeletal height but bone size and volume as well. In addition, the reduced muscle mass and strength and increased fat mass of GHD patients may indirectly influence bone metabolism.
We have evaluated the impact of GHD on bone mass, size, and mineral density and on fracture incidence in a group of adult hypopituitary GHD patients who had not been treated adequately with GH during childhood. To study patients in whom GHD had affected bone development from early childhood onwards, we selected only patients with an idiopathic cause, which can be assumed to have had its onset in early childhood. Some patients had been exposed to GH therapy, but as confirmed by the actual height values, the treatment periods had been too short to significantly affect adult outcomes. Bone mass was severely affected at all sites (Ϫ29 to Ϫ58%), substantially more than the relative deficit in height (Ϫ16 to Ϫ20%) would predict. Assuming that the relative height difference would also apply for the two other bone dimensions, however, the calculated relative bone volume would also be only 61% for patients with IGHD and 59 and 51% for patients with OMPHD and CMPHD, respectively. Therefore, the estimated reduction of total bone volume approximates the measured reduction in bone mass. The discrepancy with the relative height deficit is impressive (Fig. 1) . We previously reported a similar type of discrepancy, although to a lesser extent, in subjects with severe COGHD who had been treated with GH during childhood (6) . Their height deficit was about 3-5% (Ϫ1 sd) of agematched controls, but their total bone mass was only 80% of age-matched controls (6) . Taken together, these data suggest that, especially in GH-untreated but also in GH-treated COGHD patients, bone size and volume are significantly more affected than skeletal height.
For fracture prediction, BMD rather than bone mass (BMC) has been used in nearly all clinical prospective studies (14, 15) . DEXA measures bone mass and projected surface area and uses both parameters to calculate areal BMD (16) . This measure, however, underestimates the volumetric density in case of reduced bone size (small height) (14) . Therefore, it is not surprising that in our patients areal BMD was severely reduced (Table 3 ) but mean volumetric BMD was normal after closure of the growth plates. This was the case in the younger IGHD as well as the much older CMPHD patients (Table 3 ). This indicates that COGHD equally affects bone size and BMC but that the remaining low bone volume is adequately mineralized. These data also suggest that suboptimal hormone replacement of other pituitary hormone deficiencies, as might have been the case in some of our MPHD patients, does not cause a further deterioration of volumetric bone density beyond that observed with IGHD. These observations are in line with previous studies reporting normal volumetric BMD in GHD patients who had been adequately treated with GH during childhood (3, 17, 18) . Compared with IGHD and CMPHD patients, volumetric BMD in OMPHD patients was lower, but this can be assumed to be due to sex steroid hormone deficiency and delayed substitution and the resulting considerable retardation in their pubertal bone age.
Although the methodology used in the present study did not address directly the relative deficit of cortical vs. trabecular bone, the radiogrammetry results indicate that bone width was severely impaired in all of our patients ( Table 4) . The deficit in cortical metacarpal area (ϳ70% of control) is comparable to that seen for total-body BMC, which also reflects better cortical than trabecular bone mass. Such a deficit of cortical bone could also explain why the fractures occur especially in bones with predominant cortical bone (see below). Indeed, the bending strength of bone is proportional to the fourth power of its distance to the central axis of long bones (19) . The lifetime prevalence of nontraumatic fractures in 66 Russian patients with COGHD was calculated on the basis of a detailed questionnaire and compared with similar data obtained in 186 young (25 Ϯ 5 yr) and 147 older (53 Ϯ 12 yr) normal Russian control subjects. OMPHD patients were compared with the young controls, and CMPHD patients were compared with the older controls.
The incidence or prevalence of fractures in GHD patients has been evaluated previously in three cross-sectional studies (20 -22) and in one observational database (23) . A 2-(20, 21) to 4.9-fold (23) increase in fracture risk was observed in GHD patients with substituted MPHD, and a similar trend was also found in a limited number of older IGHD patients (22) . Data on adults with lifelong untreated COGHD are virtually nonexistent. In the present study, we found a low prevalence of fractures in young adults with IGHD, which is in agreement with published data in GH-treated COGHD patients (18) . The discrepancy between the prevalence of fractures in young patients with IGHD and older patients with MPHD is obvious but unresolved. Unfortunately, we were unable to find sufficient, older, GH-untreated IGHD patients to assess their lifetime fracture prevalence. On the other hand, the significantly reduced bone size and volume found in our young IGHD adults is identical to that of the older MPHD patients. Moreover, previous studies have found identical bone histology and bone turnover markers in IGHD and MPHD patients (24, 25) . This suggests that the quality of bone is not different in both conditions. Therefore, the low BMC values of IGHD patients probably also carry a high risk of fractures at older ages, but only specific data can validate this conclusion. Conversely, our data in both MPHD groups show that fractures are an early complication of combined GHD and MPHD in the absence of GH treatment, specifically if hormonal replacement of other hormone deficiencies has not been adequate. Compared with controls, MPHD patients had a 3-to 7-fold increased fracture prevalence (Table 5) . At a mean age of 55 yr, CMPHD patients had, on average, 2.2 fractures per patient with 37 and 62% of patients having sustained at least one or at least two fractures, respectively. The sample size of the present study was too small to evaluate gender differences in fracture rates. The fracture prevalence of 16 -18% found in the Russian control subjects is very consistent with an 18% prevalence reported in a Finnish study (7217 women with a mean age of 53 yr) (26) . The fracture prevalence of untreated GHD Russian adults even exceeds the lifetime fracture prevalence observed in Rochester anorexia nervosa patients (27) .
Nearly all fractures involved the radius or other bones (hand/foot, tibia) whereby cortical bone strength is probably involved. Because volumetric BMD is normal in CMPHD patients and only one Z score below normal in OMPHD patients, one can conclude that reduced bone mass, bone size, or bone quality are the main culprits and not volumetric density. Because no structural abnormalities but only a decreased bone turnover have been found in adult GHD patients (24) , bone size and associated low bone mass seem to be the causative factors. Similarly, because gender differences in volumetric bone density are small (13, 28) , differences in fracture prevalence between females and males might be more related to gender differences in the geometry of bone.
Our data and conclusions are supported by findings in other clinical situations with impaired GH-IGF-I axis. Short stature, decreased BMC, and decreased areal BMD, but normal volumetric bone mineral apparent density, were also reported in patients with GH receptor deficiency (Laron patients), GHRH receptor deficiency (25, 29) , and mutations of the IGF-I gene (30) . In addition, normal structure of trabecular and cortical bone was described in COGHD adults (24) and in GH receptor-deficient patients (25) . Finally, in GH receptor and IGF-I knockout mice (31, 32) , total-body calcium and areal BMD are decreased, but volumetric BMD is normal. Total-body BMC is reduced to the same extent as body weight in the GHRH receptor-deficient (little) mouse, which displays a growth pattern very similar to that of GHD rodents (33) .
These human and animal data strongly indicate that COGHD, and not the other pituitary hormone deficiencies, determines bone size and mass. Because we do not have an older group of IGHD patients, we cannot extend this conclusion to fracture prevalence. Do these results have implications for non-GHD adults? Indeed, we think that the present study clearly reveals the importance of geometry and size as a major determinant, apart from density and quality, for bone strength and fracture risk. Recent long-term prospective data on postmenopausal women indicate that section modulus, a geometric parameter calculated mainly on the basis of bone width, is a substantially better predictor of fractures than BMD (34) .
In conclusion, bone mass is severely (Ϯ 50%) reduced in GH-untreated patients with idiopathic COGHD, irrespective of the presence of other pituitary hormone deficiencies. Lifetime nontraumatic fracture prevalence is significantly increased when GHD is coupled with MPHD. Further study is needed to determine whether IGHD is associated with an increased risk of fractures. The present study demonstrates not only the critical role of GH in the development and maintenance of normal bone but also that bone mass and size, rather than volumetric density, are major determinants of bone strength.
